Cuprina Holdings, a Singapore-based biomedical and biotechnology company, has announced the completion of its in-vitro fertilisation (IVF) media production facility in Singapore. The facility, built in collaboration with Ferti-Craft Pte Ltd, has received ISO 13485 certification and a dealer licence from the Singapore Health Sciences Authority. This marks a significant milestone for the company as it aims to produce 14 different IVF media products by the fourth quarter of 2026.
The ISO 13485 certification, issued by the United Kingdom Accreditation Service, confirms that the facility meets international standards for medical device manufacturing. The dealer licence allows Cuprina to legally operate in manufacturing, importing, or wholesaling medical devices. The facility will produce IVF media containing essential nutrients and materials to stimulate fertilisation in vitro.
Cuprina will work with Ferti-Craft to prepare regulatory dossiers for the Singapore Health Sciences Authority, aiming for commercial sale approval by late 2026. Ferti-Craft will handle documentation, testing certificates, and logistics for raw materials, leveraging its expertise in human assisted reproductive technology.
David Quek, Cuprina’s CEO, expressed enthusiasm for the collaboration, stating, “We are very excited to be collaborating with Ferti-Craft on this IVF media production facility, the first of its kind in Singapore to be established by a Singapore company.” Jai Thampi, co-founder of Ferti-Craft, added that Cuprina’s experience and flexibility were key factors in forming the strategic partnership.
The global market for assisted reproductive technology, valued at $34.7b in 2023, is projected to grow significantly, driven by rising infertility rates and increased acceptance of ART technology. Cuprina’s new facility positions the company to tap into this expanding market, with initial sales expected in Singapore and plans to expand into ASEAN countries, the Middle East, and beyond.
